Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

552 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study.
Oki E, Emi Y, Kojima H, Higashijima J, Kato T, Miyake Y, Kon M, Ogata Y, Takahashi K, Ishida H, Saeki H, Sakaguchi Y, Yamanaka T, Kono T, Tomita N, Baba H, Shirabe K, Kakeji Y, Maehara Y. Oki E, et al. Among authors: kon m. Int J Clin Oncol. 2015 Aug;20(4):767-75. doi: 10.1007/s10147-015-0784-9. Epub 2015 Jan 28. Int J Clin Oncol. 2015. PMID: 25627820 Clinical Trial.
Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
Yanagimoto H, Satoi S, Sho M, Akahori T, Yamamoto T, Hirooka S, Yamaki S, Kotsuka M, Ryota H, Kinoshita S, Nishiwada S, Nagai M, Ikeda N, Tsuta K, Nakajima Y, Kon M. Yanagimoto H, et al. Among authors: kon m. Cancer Chemother Pharmacol. 2016 Jan;77(1):35-41. doi: 10.1007/s00280-015-2928-z. Epub 2015 Dec 8. Cancer Chemother Pharmacol. 2016. PMID: 26645403 Clinical Trial.
Phase I Study of Sorafenib in Combination with Intermittent Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma.
Ishizaki M, Kaibori M, Matsui K, Ikeda H, Yoshida K, Okazaki K, Kariya S, Tanigawa N, Nakatake R, Matsushima H, Sakaguchi T, Kon M. Ishizaki M, et al. Among authors: kon m. Cancer Invest. 2017 Apr 21;35(4):271-276. doi: 10.1080/07357907.2017.1289382. Epub 2017 Mar 8. Cancer Invest. 2017. PMID: 28272913 Clinical Trial.
552 results